Young, Peter http://orcid.org/0000-0002-4818-4270
Heeman, Fiona http://orcid.org/0000-0001-7769-8329
Axelsson, Jan http://orcid.org/0000-0002-3731-3612
Collij, Lyduine E. http://orcid.org/0000-0001-6263-1762
Hitzel, Anne
Sanaat, Amirhossein http://orcid.org/0000-0001-8437-2060
Niñerola-Baizan, Aida http://orcid.org/0000-0002-7306-5775
Perissinotti, Andrés http://orcid.org/0000-0003-4190-2425
Lubberink, Mark http://orcid.org/0000-0001-8324-7399
Frisoni, Giovanni B. http://orcid.org/0000-0002-6419-1753
Zaidi, Habib http://orcid.org/0000-0001-7559-5297
Barkhof, Frederik http://orcid.org/0000-0003-3543-3706
Farrar, Gill http://orcid.org/0000-0002-0726-723X
Baker, Suzanne http://orcid.org/0000-0003-0209-3127
Gispert, Juan Domingo http://orcid.org/0000-0002-6155-0642
Garibotto, Valentina http://orcid.org/0000-0003-2422-698X
Rieckmann, Anna http://orcid.org/0000-0002-5389-1578
Schöll, Michael http://orcid.org/0000-0001-7800-1781
,
Funding for this research was provided by:
Innovative Medicines Initiative (115372, 115952)
University of Gothenburg
Article History
Received: 11 July 2023
Accepted: 15 October 2023
First Online: 28 October 2023
Declarations
:
: FB is supported by the NIHR biomedical research centre at UCLH. He is steering committee or Data Safety Monitoring Board member for Biogen, Merck, ATRI/ACTC and Prothena. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics and has research agreements with Merck, Biogen, GE Healthcare, Roche. He is also co-founder and shareholder of Queen Square Analytics LTD. JDG holds a ‘Ramón y Cajal’ fellowship (RYC-2013–13054) from the Spanish Ministry of Science, Innovation and Universities, has received research support from GE Healthcare, Roche Diagnostics and Hoffmann–La Roche, and speaker or consultant fees from Philips Nederlands and Roche Diagnostics. VG reports grants from the Swiss National Science Foundation (projects:320030_169876, 320030_185028 and IZSEZ0_188355), the Velux foundation (project:1123) and she received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck. MS has served on advisory boards for Servier, Roche and Novo Nordisk (outside scope of submitted work) and receives funding from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363, KAW2023.0371), the Swedish Research Council (2017–02869, 2021–02678 and 2021–06545), the Swedish State under the Agreement Between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971 and ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311) and the Swedish Alzheimer Foundation (AF-740191). GBF is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A.—Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Race Against Dementia Foundation, London, UK; Fondation Child Care, Genève; Fondation Edmond J. Safra, Genève; FondationMinkoff, Genève; Fondazione Agusta, Lugano; McCall Macbain Foundation, Canada; Nicole et René Keller, Genève; Fondation AETAS, Genève. GBF has received funding for research projects from: H2020, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation; has received unrestricted grants and support for event organisation from ROCHE Pharmaceuticals, OM Pharma, EISAI Pharmaceuticals, Biogen Pharmaceuticals. The Clinical Research Center, at Geneva University Hospital and Faculty of Medicine provides valuable support for regulatory submissions and data management, and the Biobank at Geneva University Hospital for biofluid processing and storage. LC has received research support from GE Healthcare and Springer Healthcare (funded by Eli Lilly). Both paid to the institution.